Showing 3351-3360 of 5257 results for "".
- Lebrikizumab Achieves Deep and Sustained Response at 3 Years in ADhttps://practicaldermatology.com/news/Lebrikizuab-Achieves-Deep-Sustained-Response-3-Years-AD/2471538/Lebrikizumab (EBGLYSS) achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at 3 years in the ADjoin long-term extension study presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, Eli Lilly and Company anno
- Topical Gel Bimiralisib Shows Promise for AK in Interim Resultshttps://practicaldermatology.com/news/Topical-Gel-Bimiralisib-Shows-Promise-AK-Interim-Results/2471537/Interim results from an ongoing Phase 2 clinical trial in actinic keratosis highlighted strong potential for the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, Torqur AG announced at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Fl
- AI Highlighted as Potential Game-Changer for GPP, HShttps://practicaldermatology.com/news/AI-Highlighted-Potential-Game-Changer-GPP-HS/2471522/Diagnosing and efficiently treating rare diseases in dermatology has long been an important challenge, and one session at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlighted how artificial intelligence (AI) can help. “Using Artificial Intelligence for Rare Dermatolog
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- TSC Reduces Tretinoin-Induced Skin Irritation: Pilot Studyhttps://practicaldermatology.com/news/tsc-reduces-tretinoin-induced-skin-irritation-pilot-study/2471409/A recent pilot study has shown that tetramethylhexadecenyl succinoyl cysteine (TSC) significantly reduces erythema and dryness caused by tretinoin application. These findings may offer a novel approach to minimizing the common adverse effects of tretinoin, potential
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Dr. Lain Discusses Predictive Modeling for PsO Biologic Selectionhttps://practicaldermatology.com/news/Dr-Lain-Discusses-Predictive-Modeling-PsO-Biologic-Selection/2471252/Edward (Ted) Lain, MD, MBA, reminded attendees at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, that a method exists for selecting the best class of biologic for each psoriasis patient. “I just want to keep this in the public conscience here,” Dr. Lain said. “There i